The American Academy of Dermatology (AAD) Annual Meeting was held from March 7-11 in Orlando, Florida. This event is widely regarded as the foremost dermatology education event of the year, providing attendees with the chance to participate in a comprehensive program led by experts in the field of dermatology. It also offers a valuable opportunity to expand professional networks by connecting with peers and industry leaders.
Outlined below are brief summaries of research studies presented at the AAD Annual Meeting that focus on psoriasis.
Real-world clinical experience with bimekizumab in the treatment of palmoplantar psoriasis
- Palmoplantar psoriasis (PPP) presents a significant therapeutic challenge and can have a profound impact on a patient's quality of life. Bimekizumab, an interleukin (IL) 17-A and 17-F inhibitor, has been approved for the treatment of moderate to severe plaque psoriasis (PP). Given the potential synergistic effect of IL 17 and 36 in the physiopathogenesis of PPP, bimekizumab may offer promise in treating this condition. While clinical trials have shown the efficacy and safety of bimekizumab in treating PP, there is a lack of real-world data on its performance in treating PPP. To address this gap, the researchers conducted an observational retrospective study that included all patients who received bimekizumab for PPP at our center, with a follow-up period of 6 months.
- The findings suggest that bimekizumab, when used in real-life clinical practice for PPP, leads to rapid and consistent improvement with a favorable safety profile in the short term. However, it is important to note that patients with PPP often have other challenging-to-treat areas and may have experienced treatment failures with prior biologics.
- The primary objective of this research is to explore the prevalence of paradoxical eczema, a notable side effect associated with the use of specific biologics in the treatment of psoriasis. Our study uncovered a paradoxical eczema prevalence of 2.3% among psoriasis patients undergoing biologic therapy, which is notably higher than the previously reported prevalence of 1% in existing literature.
- The findings underscore the importance of recognizing and addressing the potential risk of paradoxical eczema when utilizing biologics for the treatment of psoriasis. By shedding light on this phenomenon, we hope to enhance the understanding and management of this challenging aspect of psoriasis therapy.
- Psoriasis is a chronic autoimmune skin condition that is often linked to cardiovascular diseases, metabolic abnormalities, sleep disorders, and depression. Interestingly, certain biologics used to treat psoriasis can actually trigger eczema, leading to increased itching and sleep disturbances that can significantly impact a patient's quality of life. This research aims to delve into the prevalence of this paradoxical eczema, which is a notable side effect of some biologics commonly used in psoriasis treatment.
- In this extensive cohort study involving psoriasis patients, the researchers found that IL-23 inhibitors were associated with a reduced likelihood of developing dyslipidemia, hypertension, diabetes, and major adverse cardiovascular events (MACE) when compared to other classes of biologics. This discovery sheds light on the potential benefits of IL-23 inhibitors in managing not only psoriasis but also the associated comorbidities.
- Psoriasis is a chronic skin disease with a complex etiology that impacts approximately 6.9 million adults in the United States. Recent studies have suggested that insufficient levels of vitamin B12 may play a role in the development of psoriasis, with hyperhomocysteinemia (HHcy) being more prevalent among psoriasis patients. However, further research is needed to fully understand this potential link.
- Research has shown a significant association between psoriasis and vitamin B12 deficiency, particularly in adults between the ages of 40 and 59. Moving forward, it is crucial to delve deeper into the pathophysiology of this relationship and explore the potential clinical implications of using vitamin B12 in the management of psoriasis.
- Psoriasis, whether on the scalp or body, significantly impacts the quality of life for patients, with pruritus being identified as the most burdensome symptom. Roflumilast foam 0.3% is a groundbreaking, once-daily treatment that acts as a potent phosphodiesterase 4 inhibitor, specifically designed for the management of scalp and body psoriasis.
- The ARRECTOR phase 3 trial (NCT05028582) focused on patients aged 12 years and older who were experiencing moderate scalp psoriasis according to the Scalp-Investigator Global Assessment (S-IGA), and mild body psoriasis according to the Body-IGA (B-IGA), affecting no more than 25% of the body surface area. The results of the trial demonstrated that treatment with roflumilast foam 0.3% led to significant improvements in patient-reported outcomes and overall quality of life for individuals suffering from scalp and body psoriasis.
- The objective of this study is to compare the Body Mass Index (BMI) and prevalence of metabolic syndrome between male and female patients with psoriasis. Additionally, we aim to assess the differences in BMI between patients with Type 1 psoriasis (onset before 40 years old) and Type 2 psoriasis (onset after 40 years old).
- The findings indicate a significant correlation between elevated BMI, type of psoriasis, and the presence of metabolic syndrome. Specifically, male patients and those with Type 2 psoriasis are more likely to be overweight and experience metabolic syndrome.
- SYSA1902 is a biosimilar to ustekinumab, a medication used to treat moderate-to-severe plaque psoriasis. The purpose of this study (CHiCTR2300069534) was to assess the effectiveness and safety of SYSA1902 in comparison to reference ustekinumab in patients with this condition.
- The results of the study indicate that SYSA1902 is just as effective as ustekinumab in treating moderate-to-severe plaque psoriasis. This suggests that SYSA1902 could be a viable alternative for patients seeking treatment for this condition.
The #AAD2025 is set to be an enriching and informative event. We recommend clicking here to explore the comprehensive list of topics and sessions that will be covered at this significant event. Don’t miss the opportunity to expand your expertise.
Sign up for alerts and stay informed on the latest published guidelines and stay tuned for our recap post the conference.
Copyright © 2025 Guideline Central, All Rights Reserved.